Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

RESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

Moderna (MRNA) announced that the Medicines ... the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older. The approval is based ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.